Emanuel Garcia, who owns a Mexican store in the city’s Esperanza neighborhood, has seen his business take a huge hit during the COVID-19 pandemic. A Rutgers Global Health Institute program helped him stay open and continue serving the community’s needs safely.
Rutgers University Behavioral Health Care hired an additional 30 mental health clinicians this summer, specifically to work with school districts to promote the social and emotional health of the state’s students, teachers, and staff as the pandemic continues.
Vaccine access amid political turmoil in Venezuela is the backdrop of institute director Richard Marlink’s comments, for a story published by Devex, about COVAX and a global response to the pandemic.
It’s been a year since COVID-19 was declared a global pandemic. Rutgers Global Health Institute core faculty members discuss the health crisis in relation to their own areas of expertise and professional practice.
In an interview with The Daily Targum, institute director Richard Marlink explains the international collaboration to distribute COVID-19 vaccines more equitably worldwide.
The three-part program provides guidance on safe operations and related support services for small businesses and nonprofits in New Jersey’s low-income and minority communities.
Following the FDA’s emergency approval of Johnson & Johnson’s COVID-19 vaccine, ROI-NJ published a collection of health experts’ perspectives that includes institute director Richard Marlink’s comments about vaccine efficacy.
In an interview for WRSU Rutgers Radio, institute director Richard Marlink offers perspective on the importance of a global response to COVID-19, vaccine infrastructure in Africa, vaccine production and safety, and the World Health Organization.
The importance of a global COVID-19 vaccination strategy and how WHO involvement benefits the U.S. overall are topics that institute director Richard Marlink discusses in this Q&A.
Appearing on CNBC’s Power Lunch, core faculty member and Rutgers vice chancellor Reynold Panettieri discusses the Johnson & Johnson COVID-19 vaccine, infection rates and hospitalizations, and effective public health measures.
